Statin use and risk of nonmelanoma skin cancer: a nationwide study in Denmark
A partir des données du registre danois des cancers portant sur 38 484 cas de carcinome basocellulaire cutané, 3 724 cas de carcinome épidermoïde cutané et autant de témoins en population, cette étude évalue l'association entre l'utilisation de statines et le risque de cancer de la peau hors mélanome, sur la période 2005-2009
Background: Evidence is conflicting regarding statin use and risk of basal cell (BCC) and squamous cell skin cancer (SCC). Methods: Using Danish nationwide registries, we identified all patients with incident BCC/SCC during 2005–2009 and matched them to population controls. We computed odds ratios (ORs) for BCC and SCC associated with statin use. Results: We identified 38 484 cases of BCC and 3724 cases of SCC. Statin ever use was associated with ORs of 1.09 (CI: 1.06–1.13) for BCC and 1.01 (CI: 0.91–1.11) for SCC. Conclusions: Statin use was not associated with risk of SCC. Residual confounding plausibly explains the marginally increased risk of BCC.